

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. (Currently amended) A vaccine composition comprising (a) an antigen and (b) an immunoadjuvant compound, wherein said immunoadjuvant compound consists of a Rho GTPase activator belonging to the protein families of DNT and CNF1.

2. (Currently amended) A vaccine composition ~~according to claim 1~~ comprising (a) an antigen and (b) an immunoadjuvant wherein said immunoadjuvant compound consists of a Rho GTPase activator ~~is~~ selected from the group consisting of:

- a polypeptide comprising the amino acid sequence starting at the amino acid residue 720 and ending at the amino acid residue 1014 of sequence SEQ ID ~~Nº1~~ NO 1,

- a polypeptide comprising the amino acid sequence starting at the amino acid residue 720 and ending at the amino acid residue 1014 of sequence SEQ ID ~~Nº2~~ NO 2,

- a polypeptide comprising the amino acid sequence starting at the amino acid residue 720 and ending at the amino acid residue 1014 of sequence SEQ ID ~~Nº3~~ NO 3, and

-a polypeptide comprising the amino acid sequence starting at the amino acid residue 1146 and ending at the amino acid residue 1451 of sequence SEQ ID ~~N°4~~ NO 4.

~~-a polypeptide comprising the amino acid sequence SEQ ID~~
~~N°5,~~

~~-a polypeptide comprising the amino acid sequence SEQ ID~~
~~N°6,~~

~~-a polypeptide comprising the amino acid sequence SEQ ID~~
~~N°7,~~

~~-a polypeptide comprising the amino acid sequence SEQ ID~~
~~N°8, and~~

~~-a polypeptide comprising the amino acid sequence SEQ ID~~
~~N°9.~~

3. (Currently amended) A vaccine composition according to claim ~~1~~ 2 wherein said immunoadjuvant compound is selected from the group consisting of :

-a polypeptide comprising the amino acid sequence SEQ ID
~~N°1~~ NO 1,

-a polypeptide comprising the amino acid sequence SEQ ID
~~N°2~~ NO 2,

-a polypeptide comprising the amino acid sequence SEQ ID
~~N°3~~ NO 3, and

-a polypeptide comprising the amino acid sequence SEQ ID
~~N°4~~ NO 4.

4. (Currently Amended) A vaccine composition according to claim ~~±~~ 2, comprising (a) an antigen and (b) an immunoadjuvant, wherein said immunoadjuvant compound is a protein comprising a polypeptide consisting of ~~+~~ +, from the N-terminal end to the C-terminal end, ~~respectively: the injection domain of a Rho GTPase activator, and~~

~~a) the catalytic domain of a Rho GTPase activator.~~

- (i) a first polypeptide selected from the group consisting of :

- a polypeptide comprising the amino acid sequence starting at the amino acid residue 1 and ending at the amino acid residue 719 of sequence SEQ ID NO 1,

- a polypeptide comprising the amino acid sequence starting at the amino acid residue 1 and ending at the amino acid residue 719 of sequence SEQ ID NO 2,

- a polypeptide comprising the amino acid sequence starting at the amino acid residue 1 and ending at the amino acid residue 719 of sequence SEQ ID NO 3, and

- a polypeptide comprising the amino acid sequence starting at the amino acid residue 1 and ending at the amino acid residue 1145 of sequence SEQ ID NO 4; and

(ii) a second polypeptide selected from the group consisting of :

- a polypeptide comprising the amino acid sequence

starting at the amino acid residue 720 and ending at the amino acid residue 1014 of sequence SEQ ID NO 1,

- a polypeptide comprising the amino acid sequence starting at the amino acid residue 720 and ending at the amino acid residue 1014 of sequence SEQ ID NO 2,

- a polypeptide comprising the amino acid sequence starting at the amino acid residue 720 and ending at the amino acid residue 1014 of sequence SEQ ID NO 3, and

- a polypeptide comprising of the amino acid sequence starting at the amino acid residue 1146 and ending at the amino acid residue 1451 of sequence SEQ ID NO 4.

5-7. (Cancelled)

8. (Currently Amended) A vaccine composition according ~~to claim 7~~ any one of claims 1 to 4 wherein the antigen is selected from the group consisting of a hormone, a protein, a drug, an enzyme, a vaccine composition against bacterial, viral, fungal, prion, or parasitic infections, a component produced by microorganisms, inactivated bacterial toxins such as cholera toxin, ST and LT from Escherichia coli, tetanus toxin from Clostridium tetani, and proteins derived from HIV viruses.

9. (Currently Amended) A vaccine composition according to ~~claim 1~~ any one of claims 1 to 4 for administration to a mucosal surface.

10. (Currently Amended) A vaccine composition according to ~~claim 1~~ any one of claims 1 to 4 for an oral administration.

11-14. (Cancelled)

15. (currently amended) A method for preparing a ~~comprising, composition~~ adding ~~polypeptide according to claim 1~~ the immunoadjuvant as defined in any one of claims 1 to 4 to an excipient.

16. (Cancelled)